AMPH: Multiplikator P/S Amphastar
Rising Glucagon sales and the launch of new generics are driving shares higher, as confirmed by the price-to-sales valuation on the GURU.Markets system chart, where the value 1.60 describes the current level. A stable staff of analytical chemists and a loyal R&D center support production. High clinical confidence in the quality of injectable systems solidifies the reputation of Amphastar Pharmaceuticals (AMPH) as a reliable brand.
Rincian analitis perusahaan Amphastar (AMPH)
- rega saham lan konsensus proyeksi valuasi:
- informasi kapitalisasi pasar:
- data ekuitas miturut neraca:
- indikator beban kredit lan likuiditas emiten:
Rasio Kabeh Utang marang Dana Pribadi Amphastar Pharmaceuticals|AMPH - Utang jangka dawa marang modal|Utang jangka cendhak marang modal Amphastar Corp|AMPH - Utang perusahaan|Utang-utang marang aset resik Amphastar|AMPH - Kewajiban jangka dawa perusahaan|Gedhene kewajiban jangka cendhak Amphastar Pharmaceuticals|Rasio cepet amphastar.com
- data bathi bisnis lan rasio investasi:
AMPH - Bathi resik perusahaan|Penghasilan resik sing dikarepake Amphastar Pharmaceuticals|AMPH - Koefisien rega marang bathi|Pangali mangsa ngarep rega marang bathi Amphastar Pharmaceuticals Inc|AMPH - Rasio rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi operasional sadurunge panyusutan Amphastar|AMPH - Bathi operasional EBITDA|Bathi saben saham sajroning taun lumaku Amphastar Pharmaceuticals|AMPH - Bathi resik saben saham (EPS TTM)|Wutah bathi EPS kuartalan amphastar.com|AMPH - Wutah bathi saben saham ing taun lumaku|Dinamika bathi saben saham sing diarepake ing taun ngarep Amphastar Pharmaceuticals
- data total pendapatan lan volume dodolan:
Analisis fundamental perusahaan:AMPH, amphastar.com
Utilizing external outsourcing for testing and packaging allows Amphastar Pharmaceuticals (AMPH) to flexibly scale sales while optimizing capital expenditures. The price-to-sales ratio trend reflects the market's valuation of this efficiency by comparing the business value to annual revenue; an increase in this multiple signals inflated investor expectations, which raises the risk of a correction should any deviation from the product implementation plan occur.
Karo sapa Amphastar Pharmaceuticals saingan
HLN (haleon.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S KVUE (Kenvue)|Multiplikator P/S Verona Pharma PLC VRNA|MENS - Rasio rega marang pendapatan|Ligand Corp (LGND) - Kapitalisasi marang pendapatan|Amneal Pharmaceuticals (AMRX) - Rasio rega marang pendapatan|Rasio rega marang dodolan PRGO (perrigo.com)|ALVO (Alvotech SA) - Multiplikator P/S|LQDA: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S GLPG|Multiplikator P/S ANI Pharmaceuticals Corp (ANIP)|Rasio rega marang pendapatan MannKind Corporation MNKD|Koefisien rega marang pendapatan pacira.com (PCRX)|SPRY: Kapitalisasi marang pendapatan|Theravance Biopharma Inc - Kapitalisasi marang volume dodolan|AQST: Multiplikator P/S|scPharmaceuticals (SCPH) - Multiplikator P/S|Rasio rega marang pendapatan Tectonic Therapeutic Inc.|TNXP: Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan SXTC (China SXT Pharmaceuticals)|EPRX (eupraxiapharma.com) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan BioHarvest BHST|EXOZ (Invizyne) - Rasio rega marang dodolan|Oramed Pharma - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan ENTX (Entera Bio Ltd.)|HYFT: Multiplikator P/S|ABVC BioPharma Inc. (ABVC) - Multiplikator P/S|Rasio rega marang pendapatan Cumberland Pharma|QNTM: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan FibroGen, Inc. (FGEN)|Kapitalisasi marang pendapatan telomirpharma.com TELO|Multiplikator P/S RANI (Rani Therapeutics Holdings, Inc.)|Multiplikator P/S Synergy CHC Corp. SNYR|Rallybio Corp. - Multiplikator P/S|Lexaria Bioscience (LEXX) - Kapitalisasi marang pendapatan|PULM: Multiplikator P/S|Rega marang dodolan Pheton Holdings (PTHL)|Kapitalisasi marang pendapatan APM|Multiplikator P/S Lyra Therapeutics Inc.|Kapitalisasi marang pendapatan IBO (Impact BioMedical)|Kapitalisasi marang volume dodolan TNFA|Multiplikator P/S YCBD (cbdMD)|Koefisien rega marang pendapatan painreform.com (PRFX)|Auris Medical - Multiplikator P/S|Lipella Pharmaceuticals Inc (LIPO) - Kapitalisasi marang pendapatan|OPTN: Multiplikator P/S|Pieris Pharma (PIRS) - Multiplikator P/S|Rasio rega marang pendapatan Procaps Group S.A.|Rasio rega marang pendapatan PTPI|Rasio rega marang pendapatan Qilian International Holding (QLI)|Koefisien rega marang pendapatan Acelyrin Inc.|Multiplikator P/S TFFP (TFF Pharma)
